Dexamethasone in severe respiratory COVID 19 saves lives---"Hot of the Press"
Dr. RR Baliga's 'Podkast for the Kurious Doc'
Release Date: 06/16/2020
Stop. Test. Rethink: The Thyroxine Turning Point 🔄🧠💊
Dr. RR Baliga's 'Podkast for the Kurious Doc'
🧠💊 Stop. Test. Rethink. A compelling new study in JAMA shows that ~26% of adults ≥60 years can safely discontinue levothyroxine, maintaining normal thyroid function—especially those on low doses (≤50 μg/day). 📉 No meaningful decline in quality of life 📊 Clear dose-response signal ⚠️ Raises concerns about lifelong overtreatment The message is elegant: Not every prescription deserves permanence. Time to reassess, deprescribe, and individualize—particularly in our older patients. #Thyroid #Endocrinology #Deprescribing #Geriatrics...
info_outline
Reversing Heart Failure: Where immunology meets cardiology
Dr. RR Baliga's 'Podkast for the Kurious Doc'
A fascinating step forward in Nature—where immunology meets cardiology. 🧬❤️ This study shows that engineered dendritic cells can locally reprogram the immune response, reduce fibrosis, and improve cardiac function—without systemic immunosuppression. The insight is simple, yet profound: 👉 Heart failure is not just hemodynamic—it is immunologic. From FAP-targeted delivery to checkpoint-mediated tolerance (PD-L1, CTLA4-Ig, IL-10), this work opens the door to a new therapeutic paradigm—precision immunotherapy for heart failure. 🚀 The seeds of...
info_outline
Chronology vs Physiology: A Clinical Reckoning ⚖️❤️🩹
Dr. RR Baliga's 'Podkast for the Kurious Doc'
🧠⏳ Age. Biology. Truth. A compelling Perspective in the New England Journal of Medicine challenges one of medicine’s quiet assumptions: that age equals risk. Two patients may share a birth year—but not a biology. From epigenetic clocks to physiological reserve, the evidence is clear: chronologic age is an imperfect proxy for clinical decision-making ⚠️ The consequence? Missed prevention in the young, withheld therapy in the old. ✨ The opportunity? A shift toward biologically grounded, precision care—where treatment aligns not with years lived,...
info_outline
The Genetics of GLP-1 Response 🧬💊📊
Dr. RR Baliga's 'Podkast for the Kurious Doc'
Why do GLP-1 therapies transform some patients—and barely move the needle in others? 🧬💉 A recent Nature study (~28,000 participants) identifies GLP1R and GIPR variants linked to both weight loss efficacy and GI side effects. 📊 Signal: modest for weight loss, stronger for tolerability 🧠 Insight: genetics + clinical factors explain ~25% variability 🚀 Implication: early steps toward precision obesity therapeutics The future may not be “one drug fits all,” but one genome, one strategy.
info_outline
Master Athletes and Cardiovascular Risk
Dr. RR Baliga's 'Podkast for the Kurious Doc'
Master athletes challenge one of medicine’s most elegant assumptions: that fitness always protects. In the Journal of the American College of Cardiology (JACC) consensus statement on athletes with abnormal cardiovascular findings, a paradox emerges—higher fitness, yet distinct patterns of risk: atrial fibrillation, coronary calcium, myocardial fibrosis. The lesson is not to discourage exercise—but to refine our lens. For the clinician: risk stratification must be individualized. For the athlete: performance and prudence must coexist. 🏃♂️ The heart...
info_outline
Move. Maintain. Multiply: Midlife Activity and Mortality Mastery 🏃♀️
Dr. RR Baliga's 'Podkast for the Kurious Doc'
A compelling study in : sustained moderate-to-vigorous physical activity across midlife is associated with a ~50% reduction in all-cause mortality in women (target trial emulation). Not intensity, not intermittence—consistency is the signal. For clinicians, the prescription is enduring: move often, move steadily, move for life. 🏃♀️💓 #PLOSMedicine #PreventiveCardiology #LifestyleMedicine #HealthyAging
info_outline
Dhanvantari and the Birth of Ayurveda: Divine Origins. Living Science. Timeless Healing 🕉️🌿
Dr. RR Baliga's 'Podkast for the Kurious Doc'
The origins of medicine are not merely scientific—they are deeply philosophical. In our Great Doctors Series, we begin with Dhanvantari, the divine physician of Ayurveda, emerging from myth into method. From the Ocean of Milk to the clinics of today, this episode explores how healing began as a sacred science. For students and physicians alike, it is a reminder that medicine is not just practiced—it is inherited, refined, and reimagined across centuries. 🌿🩺✨ 🎬 “Before medicine became a science, it was a gift—from the gods to humanity.”
info_outline
South Asians and ACS: The SMuRF-less Paradox 🎭🧠💔
Dr. RR Baliga's 'Podkast for the Kurious Doc'
A fascinating and somewhat unsettling observation from JACC: Asia: nearly 1 in 4 STEMI patients in New Delhi had no traditional risk factors—no hypertension, diabetes, dyslipidemia, or smoking. Yet outcomes tell a different story. Despite fewer signs of heart failure at presentation, these patients had worse left ventricular dysfunction and identical in-hospital and 1-year mortality compared with those with standard risk factors. This “SMuRF-less paradox” challenges our conventional risk models. It reminds us that absence of risk factors is not absence of risk. We may need to think...
info_outline
Cardiogenic Shock: 🏥 ICU to Life Again
Dr. RR Baliga's 'Podkast for the Kurious Doc'
A thoughtful and important JACC State-of-the-Art Review reframes cardiogenic shock not as a single ICU event, but as a longitudinal survivorship journey. The article highlights recovery, remission, native heart survival, PICS, HF GDMT optimization, and the need for structured multidisciplinary postshock clinics focused on function, cognition, quality of life, and recurrent risk after discharge. A timely call to move from rescue alone to rescue plus recovery.
info_outline
Beyond Aspirin, Clopidogrel Rising: A New Era 💊➡️🧬🚀
Dr. RR Baliga's 'Podkast for the Kurious Doc'
A landmark 10-year follow-up of the HOST-EXAM trial published in The Lancet challenges a century-old assumption: aspirin may no longer be the default for lifelong secondary prevention after PCI. Clopidogrel demonstrated a sustained reduction in ischemic and bleeding events (HR 0.86, p=0.005), with benefits that accumulated over time—yet without a mortality difference. The implication is subtle but profound: we may be witnessing the quiet reshaping of antiplatelet strategy. In cardiology, tradition often lingers—but data, eventually, prevails.
info_outlineDr RR Baliga's 'Got Knowledge Doc' PodKasts for Physicians
Not Medical Advice or Opinion